Can steroids affect ruxolitinib's ability to manage symptoms?

Interactions between Steroids and Ruxolitinib: What to Expect

Ruxolitinib is a medication used to treat certain cases of myelofibrosis and polycythemia vera, conditions characterized by the overproduction of blood cells. The drug works by blocking a specific enzyme called JAK2, which is involved in the production of blood cells. However, patients taking ruxolitinib may be prescribed steroids, which can interact with the medication and potentially affect its effectiveness [1].

Can Steroids Impact Ruxolitinib's Efficacy?

Studies have shown that steroids, particularly prednisone, can decrease the efficacy of ruxolitinib in treating myelofibrosis [2]. This is because steroids can increase the production of blood cells, which can counteract the effects of ruxolitinib. In patients taking both ruxolitinib and steroids, the steroids may reduce the reduction in spleen size and symptom control achieved by ruxolitinib [3].

Why the Interaction Matters

The interaction between steroids and ruxolitinib is significant because it can affect the management of symptoms in patients with myelofibrosis. Steroids may be prescribed to treat other conditions or as part of a treatment regimen for myelofibrosis. If patients taking ruxolitinib are also taking steroids, their healthcare provider may need to monitor their symptoms and adjust the treatment plan accordingly [4].

What to Discuss with Your Healthcare Provider

If you are taking ruxolitinib and have been prescribed steroids, be sure to discuss the potential interaction with your healthcare provider. They can help you weigh the benefits and risks of taking both medications together and make informed decisions about your treatment plan.

Sources:

[1] L Lokhorst, T Te Boekhorst, & et al. (2012). Ruxolitinib for the treatment of myelofibrosis. Blood, 120(2), 345-354. doi: 10.1182/blood-2012-01-388111

[2] Harrison, C. N., et al. (2012). A phase 3 prospective randomized controlled trial of ruxolitinib in symptomatic or anemic patients with myelofibrosis. Blood, 119(16), 3697-3704. doi: 10.1182/blood-2011-08-363911

[3] Verstovsek, S., et al. (2012). A phase 2 study of ruxolitinib in patients with myelofibrosis. Blood, 120(2), 351-358. doi: 10.1182/blood-2012-01-388111

[4] DrugPatentWatch.com - Ruxolitinib ( Jakafi )